IN8bio Announces Pricing of $10.25 Million Underwritten

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

Related Keywords

New York ,United States ,Robert Flamm ,Patrick Mccall ,David Buck ,Exchange Commission ,Company Contact ,Burns Mcclellan Inc ,Hc Wainwright Co ,Nasdaq ,Private Securities Litigation Reform Act ,Registration Statement ,Annual Report ,Quarterly Report ,Nasdaq Inab ,In8bio ,Nc ,